Genmab A/S (NASDAQ:GMAB) Receives $41.33 Average Price Target from Analysts

Genmab A/S (NASDAQ:GMAB - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the thirteen research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $41.33.

GMAB has been the subject of a number of research reports. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Truist Financial reduced their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Finally, Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday.

Genmab A/S Trading Up 0.9 %

NASDAQ GMAB traded up $0.16 during trading on Friday, hitting $18.82. 1,928,595 shares of the company's stock were exchanged, compared to its average volume of 970,382. The stock's 50 day moving average price is $20.76 and its two-hundred day moving average price is $21.71. Genmab A/S has a fifty-two week low of $18.42 and a fifty-two week high of $30.50. The company has a market cap of $12.45 billion, a PE ratio of 10.82, a P/E/G ratio of 2.65 and a beta of 0.98.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Large investors have recently modified their holdings of the company. Marotta Asset Management lifted its holdings in Genmab A/S by 5.8% in the first quarter. Marotta Asset Management now owns 13,532 shares of the company's stock valued at $265,000 after buying an additional 739 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after acquiring an additional 827 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC boosted its position in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.